期刊
SCIENCE CHINA-LIFE SCIENCES
卷 64, 期 10, 页码 1602-1611出版社
SCIENCE PRESS
DOI: 10.1007/s11427-020-1874-6
关键词
AFAP1-AS1; metastasis; proliferation; anti-cancer drug; PD-1; immunotherapy
类别
资金
- National Natural Science Foundation of China [82073135, 82072374, 82003243, 81903138, 81803025]
- Natural Science Foundation of Hunan Province [2019JJ50872, 2020JJ4766]
The lncRNA AFAP1-AS1 acts as an oncogene in malignant tumors by regulating gene expression and signaling pathways, promoting tumor cell proliferation, invasion, and migration. Researchers have explored the potential application of AFAP1-AS1 as a molecular marker and therapeutic target, as well as the limitations in understanding it and future research directions.
Long non-coding RNAs (lncRNAs) have become a hotspot in biomedical research. This interest reflects their extensive involvement in the regulation of the expression of other genes, and their influence on the occurrence and development of a variety of human diseases. Actin filament associated protein 1-Antisense RNA 1(AFAP1-AS1) is a recently discovered oncogenic lncRNA. It is highly expressed in a variety of solid tumors, and regulates the expression of downstream genes and signaling pathways through adsorption and competing microRNAs, or by the direct binding to other proteins. Ultimately, AFAP1-AS1 promotes proliferation, chemotherapy resistance, and resistance to apoptosis, maintains stemness, and enhances invasion and migration of tumor cells. This paper summarizes the research concerning AFAP1-AS1 in malignant tumors, including the clinical application prospects of AFAP1-AS1 as a potential molecular marker and therapeutic target of malignant tumors. We also discuss the limitations in the knowledge of AFAP1-AS1 and directions of further research. AFAP1-AS1 is expected to provide an example for studies of other lncRNA molecules.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据